Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Browse Research
  • Browse News
  • About Our Research
  • Transplant Enews

  • Research and News
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020
+ More Topics

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019
    Rashidi A, et al., Blood Advances – This large-scale retrospective study compared outcomes of adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) undergoing haploidentical hematopoietic cell transplantation (HCT) (n=336) versus 869 patients who underwent matched sibling donor (MSD) HCT. Results indicate that both cohorts had comparable overall survival, leukemia-free survival, non-relapse mortality, relapse, and grade II-IV acute GVHD.

    Read More

  • Evaluation of new GVHD prevention regimens shows promising results

    April 2019

    Bolaños-Meade J, et al., The Lancet Haematology – In a prospective, phase II trial, researchers found that tacrolimus, mycophenolate mofetil, with post-hematopoietic cell transplant (HCT) cyclophosphamide (TMMCy) produced the best GVHD-free, relapse-free survival (GRFS) for patients who received an allogeneic HCT when compared to the current standard of care.

    Read More

  • Steroid-free treatment rivals prednisone as initial GVHD therapy

    March 2019

    Pidala JA, et al., Bio Blood Marrow Transplant – Examining the feasibility of clinical- and biomarker-based risk-adapted therapy for acute graft-versus-host disease (GVHD), a recent phase II trial revealed similar complete response/partial response rates for sirolimus compared to current standard of care, prednisone.

    Read More

  • Continued vigilance needed to prevent infections for HCT recipients

    January 2019

    A recent study found late fatal infections (LFI) contributed to one-third of the deaths of both adult and pediatric patients who had survived more than 2 years after allogeneic hematopoietic cell transplantation (HCT). The results highlight the importance of ongoing monitoring and preventive measures for infect

    Read More

  • Experts Highlight Latest Advances in Immunotherapies for Hematologic Diseases

    July 2018
    Paczesny S, et al. Blood – This series in the journal Blood outlines both current obstacles and new opportunities for the future on a selection of emerging immunotherapies now available to patients with hematologic diseases.

    Read More

  • Ruxolitinib Can Prevent Acute GVHD in Patients with Myelofibrosis

    July 2018
    Kröger N, et al. Biol Blood Marrow Transplant – Ruxolitinib is approved for treating myelofibrosis and also has shown efficacy in treating steroid-resistant acute and chronic graft-versus-host disease (GVHD).

    Read More

  • Spotlight on Novel Therapies to Improve Post-HCT Graft-Versus-Leukemia Effects

    April 2018
    Zeiser R, et al. Blood – The latest research in cellular therapies, antibody-based treatments, and tyrosine kinase inhibitor (TKI)-based approaches to enhance GVL effects are outlined in articles published in a special edition of Blood.

    Read More

  • Cyclophosphamide is Effective GVHD Prophylaxis in Matched Related and Unrelated HCT

    January 2018
    Ruggeri A, et al. ASH abstract oral presentation, December 2017 – In patients with acute leukemia, post-transplant cyclophosphamide (PT-Cy) can effectively control GVHD after matched related and unrelated donor HCT, and is even more effective when combined with 1 or 2 immunosuppressive drugs.

    Read More

  • Lower Relapse and Improved Survival with Mild Acute GVHD after HCT for ALL

    December 2017
    Yeshurun M, et al. ASH abstract oral presentation, December 2017 – A large-scale multicenter study of pediatric and adult patients with acute lymphoblastic leukemia (ALL) has confirmed that HCT imparts a potent graft-versus-leukemia effect in ALL with improved survival and lower relapse in patients who experience grade I-II acute GVHD.

    Read More

  • Ibrutinib Leads to Durable Responses in Steroid-Resistant Chronic GVHD

    November 2017
    Miklos D, et al. Blood – Using the tyrosine kinase inhibitor ibrutinib to treat steroid-resistant chronic graft-versus-host disease (GVHD) can result in overall response rates of 67%, according to results of a multicenter, open-label phase 2 study of 42 transplant recipients.

    Read More

  • Review: Emerging Therapeutics to Treat Chronic GVHD

    November 2017
    Betts BC, et al. Biol Blood Marrow Transplant – Preclinical and clinical studies have significantly advanced the understanding of the pathophysiology of chronic graft-versus-host disease (GVHD), resulting in new immunomodulatory agents targeting innate immunity, early T-cell activation and signaling, T-cell migration, regulatory T cells, and B cell dysregulation.

    Read More

  • Vorinostat Can Lead to Lower Incidence of Acute GVHD

    September 2017
    Choi SW, et al. Blood – Adding vorinostat to a standard pre-transplant graft-versus-host disease (GVHD) prophylaxis can significantly lower the incidence of acute GVHD, according to results of a prospective, phase II study.

    Read More

  • Immunoglobulin Significantly Reduces Chronic GVHD Rates

    July 2017
    Finke J, et al. Lancet Haematol – Anti-human-T-lymphocyte immunoglobulin (ATLG) significantly lowers chronic graft-versus-host disease (GVHD) rates and reduces risks associated with long-term immune suppression, according to a long-term randomized study of 201 patients undergoing hematopoietic cell transplantation (HCT).

    Read More

  • Depression Prior to HCT is Prognostic of Lower Survival, Higher Acute GVHD

    March 2017
    El-Jawahri A, et al. Cancer – Pre-transplant depression requiring treatment significantly affected post-allogenic hematopoietic cell transplant (HCT) outcomes, including lower overall survival (OS) and higher risk of acute graft-versus-host disease (GVHD).

    Read More

  • Review: New Targeted Therapies to Treat or Prevent Chronic GVHD

    February 2017
    Cutler CS, et al. Blood – In this review, the authors summarize the current preclinical studies and early-phase clinical trial results on the following new chronic graft-versus-host disease (GVHD) therapeutic techniques. Many of these new approaches target specific immunologic pathways now known to play a role in chronic GVHD.

    Read More

  • New NIH Report: Recommended Follow-Up for Long-Term Survivors after HCT

    December 2016
    Battiwalla M, et al. Biol Blood Marrow Transplant – This report outlines the recommendations issued by the National Institutes of Health (NIH) Late Effects Consensus Conference to plan the next phase of hematopoietic cell transplantation (HCT) research “to ensure that no survivor is left behind.”

    Read More

  • Adding Sirolimus to Standard GVHD Prophylaxis Significantly Reduces Acute GVHD

    December 2016
    Sandmaier B, et al. ASH abstract oral presentation, December 2016 – Adding sirolimus to a standard graft-versus-host disease (GVHD) prophylaxis of mycophenolate mofetil (MMF) and cyclosporine (CSP) can significantly reduce the risks of grades II-IV and III-IV acute GVHD and non-relapse mortality (NRM), according to results of a phase 3 multi-center randomized trial presented at ASH.

    Read More

  • Biomarker Panel Can Predict Risk of Chronic GVHD

    August 2016
    Yu J, et al. J Clin Oncol – Researchers analyzing plasma samples of 53 HCT recipients identified 4 proteins that when used in a biomarker panel was prognostic of developing chronic graft-versus-host disease (cGVHD).

    Read More

  • A Biomarker-Guided Prophylaxis Strategy Reduces Acute GVHD

    May 2016
    Chang Y-J, et al. J Clin Oncol – A randomized trial of 228 patients undergoing haploidentical HCT has demonstrated that low-dose corticosteroid prophylaxis administered to patients at high risk of developing acute graft-versus-host disease (GVHD) can significantly decrease the incidence of the disease.

    Read More

  • Reduced Risk of Chronic GVHD with Post-Transplant Cyclophosphamide

    April 2016
    Mielcarek M, et al. Blood – High-dose cyclophosphamide administered after peripheral blood stem cell (PBSC) transplantation can reduce the risk of chronic graft-versus-host disease (GVHD), according to a single-center study of 43 patients.

    Read More

  • Haploidentical, Unrelated Donor HCT Outcomes Comparable in Lymphoma

    March 2016
    Kanate AS, et al. Blood – Reduced-intensity HCT using haploidentical or matched unrelated donors (URD) yields comparable outcomes, according to a study of 917 adults transplanted for lymphoma.

    Read More

  • Higher Dose of Invariant Natural Killer T Cells Improves HCT Outcomes

    March 2016
    Malard F, et al. Blood – Allogeneic HCT using peripheral blood stem cell (PBSC) grafts have better outcomes when the grafts contain large doses of invariant natural killer T (iNKT) cells, according to a single-center study of 80 consecutive patients transplanted between 2010 and 2013.

    Read More

  • Pre-HCT Depression Leads to Lower Survival, Higher Risk of Acute GVHD

    February 2016
    El-Jawahri A, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – Results of a large-scale study comparing adults with and without diagnosed depression prior to hematopoietic cell transplantation (HCT) found that those with pre-HCT depression had significantly lower survival and a higher incidence of grade II-IV acute GVHD.

    Read More

  • Improved Outcomes in HCT Recipients with Acute GVHD Over Time

    January 2016
    El-Jawahri A, et al. Biol Blood Marrow Transplant – A retrospective analysis of 427 hematopoietic cell transplantation (HCT) recipients who develop grades III or IV acute GVHD has found that outcomes have improved over time, with significantly lower transplant-related mortality (TRM) and increased overall survival (OS) in more recent transplants.

    Read More

  • Comparable Outcomes in Unrelated Donor vs. Haploidentical HCT with Cyclophosphamide

    December 2015
    Mussetti A, et al. ASH abstract oral presentation, December 2015 – Lower-intensity hematopoietic cell transplantation (HCT) using haploidentical donors and post-transplant cyclophosphamide for GVHD prophylaxis can achieve outcomes comparable to HLA-matched unrelated donor transplants, according to results of a retrospective study of 917 adults with Hodgkin or Non-Hodgkin lymphoma.

    Read More

  • Quality of Life Better After Marrow Transplant Than After PBSC Transplant

    December 2015
    Lee SJ, et al. ASH oral presentation, December 2015 – A secondary analysis of the large-scale (n=551) Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized study of unrelated donor bone marrow (BM) vs. peripheral blood stem cell (PBSC) transplant has found that BM recipients have better psychological well-being and less burdensome chronic GVHD symptoms than PBSC recipients.

    Read More

  • Non-Myeloablative Haploidentical HCT in Older Patients

    September 2015
    Kasamon YL, et al. J Clin Oncol – This retrospective, single-center study found that age had no significant effect on survival of 271 patients age 50-75 years undergoing non-myeloablative haploidentical hematopoietic cell transplantation (HCT).

    Read More

  • Ruxolitinib Effective in Treating Steroid-Refractory GVHD

    September 2015
    Zeiser R, et al. Leukemia – Ruxolitinib therapy to treat corticosteroid-refractory acute and chronic graft-versus-host disease (GVHD) in transplant recipients can achieve response rates >80%, according to a multi-center study of 95 patients treated with this JAK1/2 inhibitor.

    Read More

  • A Refined Acute GVHD Risk Score Can Predict HCT Outcomes

    April 2015
    MacMillan ML, et al. Biol Blood Marrow Transplant – Researchers examining the clinical stage and grade of acute graft-versus-host disease (GVHD) in 1,723 patients at the onset of treatment with systemic steroids have developed a new GVHD risk score that predicts response to initial therapy, survival, and transplant-related mortality.

    Read More

  • Biomarkers Predict Severity of GVHD after HCT

    January 2015
    Levine JE, et al. Lancet Haematol – A prognostic score based on the blood plasma concentration of three biomarkers can guide risk-adapted therapy at the onset of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).

    Read More

  • MMF Plus Corticosteroids Does Not Improve Acute GVHD Treatment Over Corticosteroids Alone

    November 2014
    Bolaños-Meade J, et al. Blood – This phase 3 multi-center randomized double-blinded trial examined whether mycophenolate mofetil (MMF) plus corticosteroids was superior to corticosteroids alone as initial therapy for acute GVHD.

    Read More

  • Tacrolimus-Sirolimus Comparable to Tacrolimus-Methotrexate as GVHD Prophylaxis

    August 2014
    Cutler C, et al. Blood – A phase 3 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) study of 304 randomized patients demonstrated that tacrolimus and sirolimus (Tac/Sir) was comparable to tacrolimus and methotrexate (Tac/Mtx) in preventing acute GVHD and early mortality after related donor hematopoietic cell transplantation (HCT).

    Read More

  • T Cell-Depletion Yields Low Rates of Chronic GVHD, Relapse in Patients Transplanted for AML

    September 2011
    Devine SM, et al. Biol Blood Marrow Transplant – Hematopoietic cell transplantation (HCT) using T cell-depleted grafts can yield low rates of chronic graft-versus-host disease (GVHD) and relapse in patients with acute myelogenous leukemia (AML) in first remission (CR1), according to the results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial 0303.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020